Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoyl Peroxide SCHEMBL1315128 | 0.88 | F2 (0.61) | KMT2AF2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1315921 | 0.83 | KMT2A (0.49) | KMT2AF2LMNAMAPTSMN1; SMN2 | |
| Hydrogen Peroxide SCHEMBL11489043 | 0.79 | LMNA (0.67) | KMT2AF2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1816 | 0.79 | LMNA (0.67) | KMT2AF2LMNAMAPTSMN1; SMN2 | |
| Hydrogen Peroxide SCHEMBL2929887 | 0.79 | LMNA (0.67) | KMT2AF2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL27265493 | 0.79 | LMNA (0.67) | KMT2AF2LMNAMAPTSMN1; SMN2 | |
| Benzene SCHEMBL10686034 | 0.79 | LMNA (0.67) | KMT2AF2LMNAMAPTSMN1; SMN2 | |
| Chloromethane SCHEMBL27484052 | 0.77 | TSHR (0.60) | KMT2AF2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL10392799 | 0.77 | LMNA (0.64) | KMT2AF2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL11340860 | 0.77 | LMNA (0.64) | KMT2AF2LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2072522-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-24 | — | — | EP | disclosed |
| EP-2048153-A1 | SUBSTITUTED SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | SLC5A1, SLC5A2, GCKR | KMT2A 3885/4885F2 2704/4885LMNA 3181/4885 |
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | SLC5A1, OR10J3, AKR1C3 | KMT2A 2963/4885F2 2702/4885LMNA 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.